AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04346823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Each participant started by preoxygenation of 100% oxygen for 3minutes. Then, parturients breath 1% of sevoflurane in a mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min.~Thirty seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure.The duration of ECV in addition to the level of difficulty estimated by obstetricians will be recorded. Usually, the duration of ECV does not exceed 10 minutes.~The intervention will be stopped if the woman reported severe pain, if version could not be achieved readily, or if prolonged fetal bradycardia, uterine bleeding or placental abruption occurred.~Parturient will be kept in Post Anesthesia Care Unit (PACU) for 45minutes. CTG will be monitored during PACU stay.
Study NCT04390698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site.
Study NCT04390698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid free anesthesia
Description: propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.
Study NCT04390698 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham block
Description: Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site.
Study NCT04390698 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: opioid general anesthesia
Description: propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained .
Study NCT04067531 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: treatment of BV with first Deqularum and then direkt after with vaginal clindamycin
Description: All patients will get the same treatment
Study NCT02255786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
Study NCT01943630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15% AS101 gel
Description: Administration of Topical 15% AS101 once a day (overnight)
Study NCT01943630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Administration of Vehicle once a day (overnight)
Study NCT01072279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tubaramure (Burundi)
Description: Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
Study NCT01072279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procomida (Guatemala)
Description: Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
Study NCT03292627 — intervention group
Intervention type: DEVICE
Intervention: Portable Noninvasive Hemodynamic Monitor
Description: A non-invasive monitor for estimating patient's heart contractility and cardiac output by the change of thoracic electrical bioimpedance.
Study NCT01799382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid on-site evaluation
Description: Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
Study NCT01799382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-TBNA
Description: EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
Study NCT01799382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
Study NCT03230305 — intervention group
Intervention type: OTHER
Intervention: Ethnographic interview
Description: If a patient is invited to participate in the a clinical trial, inclusion's status (included or/not) will be sought.~* If included: an ethnographic interview will be held with patient (or his representant) who agreed to participate in the clinical trial, his family caregivers, his physician(s) in charge of him and the trial and, and clinical studies technician responsible for management.~* If not included, an ethnographic interview has offered to him, his caregivers, his physician(s) in charge of him and the trial and clinical studies technician responsible for management. In parallel, the reasons for non-inclusion are collected from a pre-established epidemiological questionnaire.~If a patient is not invited to participate,an ethnographic interview will be held with his physician(s) in charge of him and the clinical trial and with clinical studies technician responsible for management.The reasons for non-invitation will be collected from an epidemiological survey multiple choices.
Study NCT02178683 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Tacrolimus and MMF.
Description: First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
Study NCT02581839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
Study NCT02581839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
Study NCT02581839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Medication: Zofran
Description: Zofran at 8mg orally. Given at the discretion of the treating physician
Study NCT02581839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Medication: Decadron
Description: decadron at 8mg orally. Given at the discretion of the treating physician
Study NCT03475875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A TEST Lens
Description: senofilcon A with new UV blocker investigational process
Study NCT03475875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A CONTROL Lens
Description: senofilcon A with new UV blocker standard process
Study NCT02923258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20mg/m2/w
Study NCT02923258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100mg/m2/q3w
Study NCT02923258 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: a total dose of 60Gy in 30fractions over 6 weeks
Study NCT02923258 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: a total dose of 60Gy in 30fractions over 6 weeks
Study NCT03059446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: Cenicriviroc immediate release tablets
Study NCT00305890 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care will include routine medical care.
Study NCT01845636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
Study NCT01845636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.
Study NCT00619151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Top Hat
Description: Implant of CarboMedics Top Hat mechanical valve.
Study NCT00619151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regent
Description: Implant of the St. Jude Medical Regent mechanical valve
Study NCT04001751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational yoga program
Description: Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga.
Study NCT03448081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNA-120
Description: SNA-120 (0.5%) active ointment
Study NCT04374565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
Description: Pathogen reduced SARS-CoV-2 convalescent plasma (1-2 units; \~200 mL each for a total of 200-400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.
Study NCT02015195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetic Acid (5%)
Study NCT03448081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle Ointment
Study NCT03625219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
Study NCT03625219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
Study NCT02159092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Monetary incentive for the CM groups is contingent on a saliva cotinine reading that indicates smoking abstinence. Participants were assessed 10 times (Mondays/Thursdays) for abstinence from smoking waterpipe verified by saliva cotinine. The maximum monetary incentives this group can receive is $192.50. The CM groups followed an escalating schedule where: 1) the dollar amount of the incentive increases by $.50 as long as the participant is abstinent at each visit;; and 2) resets to the starting incentive ($14) if the participant was non-compliant at the previous visit, but is compliant at the current visit. Also, Participants were given $10 bonus for every three consecutive compliant visits.
Study NCT02856789 — intervention group
Intervention type: OTHER
Intervention: Routine hemostasis tests
Description: Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers
Study NCT02856789 — intervention group
Intervention type: OTHER
Intervention: Fibrin structure (FS)
Description: FS will be determined on STA-R® prototype at Percy and at Stago
Study NCT02015195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate Slurry (50%)
Study NCT02856789 — intervention group
Intervention type: OTHER
Intervention: Thromboelastography (TEG)
Description: Thromboelastography will be processed on TEG® at Percy
Study NCT02856789 — intervention group
Intervention type: OTHER
Intervention: Specialized hemostasis tests
Description: Coagulation factors
Study NCT04272905 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study
Description: The participants will be asked to complete a questionnaire on their knowledge of, and attitudes towards the recording of patient care by patients or relatives/friends in the maternity unit. An investigator will be immediately available to facilitate completion of the survey and assist with understanding of the questions. The data recorded will be a mixture of nominal data (selections from a number of options using a tickbox) or ordinal (as above, but graded e.g. yes / yes with qualifiers / no). Free text will be coded and presented as nominal data or presented verbatim to illustrate points that arise.
Study NCT01193725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy (PE)
Description: Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
Study NCT01193725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
Study NCT01193725 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist
Description: This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
Study NCT04621123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent anti-SARS-CoV-2 MBT plasma
Description: Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma
Study NCT04621123 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
Study NCT00994604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: broccoli sprout extract
Description: consumption of broccoli sprout extract for 2 weeks
Study NCT00584103 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Alpha P Control
Description: Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
Study NCT02707094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomodulator
Description: The Biomodulator is a type of very low frequency TENS known as pulsed electromagnetic field therapy (PEMF). Unlike TENS devices that deliver 1-80 milliamperes of electrical current, PEMF devices deliver short bursts of electrical microamperes (millionths of an ampere) to injured tissues without producing heat or interfering with nerve or muscle function. Micro-current levels between 20-500 microampere appear to be most effective at relieving pain and inflammation and promoting tissue healing by realigning the natural electrical balance that exists within the cells that has become disrupted due to injury.
Study NCT02707094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care (Medication + Exercise)
Description: The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
Study NCT02707094 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (Medication + Exercise)
Description: The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
Study NCT00598962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Dosage dependent on clinical factors such as age, weight and patient-specific health status
Study NCT02015195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papain Slurry (70%)
Study NCT02015195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ammonia (10%)
Study NCT02015195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine (4%)
Study NCT02015195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isopropyl Alcohol (70%)
Study NCT02015195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Tap Water (40 degrees Celsius)
Study NCT00598962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin/rifampin
Study NCT02015195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Study NCT02022423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling
Description: 4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
Study NCT02022423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: 4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
Study NCT02022423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based walking program
Description: Four-month Internet-based walking program consisting of weekly step count goals
Study NCT02222129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT02222129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Study NCT03693365 — intervention group
Intervention type: PROCEDURE
Intervention: PEEP trial
Description: Positive end-expiratory pressure (PEEP) is increased from 5 to 10 cmH2O during one minute.
Study NCT00854932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided decision making
Description: In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
Study NCT03578354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine
Description: an oral drug to be swallowed
Study NCT03578354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: an oral drug to be swallowed
Study NCT03578354 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a masked placebo to be swallowed
Study NCT02901717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mino-Lok
Description: Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter.
Study NCT02901717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic lock
Description: Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
Study NCT03806595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Description: The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
Study NCT03806595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
Study NCT01187212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/Cisplatin + Sorafenib
Description: Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
Study NCT01187212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine/Cisplatin
Description: Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
Study NCT01781026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Single arm trial
Study NCT01396408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)